Patents by Inventor Angela Melton
Angela Melton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9801931Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: GrantFiled: February 23, 2015Date of Patent: October 31, 2017Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Alison D. O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
-
Publication number: 20160243210Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: ApplicationFiled: February 23, 2015Publication date: August 25, 2016Inventors: Alison D. O'BRIEN, Angela MELTON-CELSA, Michael SMITH, James SINCLAIR
-
Patent number: 8969529Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: GrantFiled: January 21, 2010Date of Patent: March 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Alison O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
-
Publication number: 20140135481Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.Type: ApplicationFiled: September 25, 2013Publication date: May 15, 2014Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Jeffrey R. Stinson, Hing Wong, Alison D. O'Brien, Clare K. Schmitt, Angela Melton-Celsa
-
Publication number: 20140023652Abstract: The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.Type: ApplicationFiled: October 2, 2013Publication date: January 23, 2014Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Michael SMITH, Angela Melton-Celsa, Alison D. O'Brien
-
Patent number: 8293245Abstract: The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.Type: GrantFiled: April 20, 2007Date of Patent: October 23, 2012Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Michael Smith, Angela Melton-Celsa, Alison O'Brien
-
Publication number: 20120195891Abstract: The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (c?Stx1) and anti-Shiga Toxin 2 (c?Stx2) antibodies.Type: ApplicationFiled: March 6, 2012Publication date: August 2, 2012Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Thallion Pharmaceuticals, Inc.Inventors: Marc Riviere, Claire Thuning-Roberson, Mariam Mehran, Alison O'Brien, Angela Melton-Celsa, Janique Sam-Pan
-
Publication number: 20110318357Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: ApplicationFiled: January 21, 2010Publication date: December 29, 2011Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Alison O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
-
Publication number: 20100189715Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.Type: ApplicationFiled: August 6, 2009Publication date: July 29, 2010Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Sunol Molecular CorporationInventors: Jeffrey R. Stinson, Hing Wong, Alison D. O'Brien, Clare K. Schmitt, Angela Melton-Celsa
-
Publication number: 20100166753Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.Type: ApplicationFiled: December 28, 2009Publication date: July 1, 2010Inventors: Jeffrey R. Stinson, Hing Wong, Alison D. O'Brien, Clare K. Schmitt, Angela Melton-Celsa
-
Publication number: 20090258010Abstract: The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (c?Stx1) and anti-Shiga Toxin 2 (c?Stx2) antibodies.Type: ApplicationFiled: May 31, 2007Publication date: October 15, 2009Applicant: Thallion Pharmaceuticals, Inc.Inventors: Marc Riviere, Claire Thuning-Roberson, Mariam Mehran, Alison O'Brien, Angela Melton-Celsa, Janique Sam-Pan
-
Publication number: 20070292426Abstract: The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.Type: ApplicationFiled: April 20, 2007Publication date: December 20, 2007Inventors: Michael Smith, Angela Melton-Celsa, Alison O'Brien
-
Publication number: 20070160607Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.Type: ApplicationFiled: June 20, 2006Publication date: July 12, 2007Inventors: Jeffrey Stinson, Hing Wong, Alison O'Brien, Clare Schmitt, Angela Melton-Celsa
-
Publication number: 20070003560Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.Type: ApplicationFiled: June 20, 2006Publication date: January 4, 2007Inventors: Jeffrey Stinson, Hing Wong, Alison O'Brien, Clare Schmitt, Angela Melton-Celsa
-
Publication number: 20030170248Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.Type: ApplicationFiled: December 18, 1998Publication date: September 11, 2003Inventors: JEFFREY R. STINSON, HING WONG, ALISON D. OBRIEN, CLARE K. SCHMITT, ANGELA MELTON-CELSA
-
Patent number: 6030388Abstract: The present invention includes a bone fixation apparatus comprising a bone fixation element, a linking member, and a coupling member. The coupling member has a first channel for receiving a portion of the bone fixation element and a second channel for receiving a portion of the linking member. The first and second channels are configured within the coupling member so as to allow communication of a securing force from the bone fixation element to the linking member such that the bone fixation element is rigidly secured with respect to the linking member. The bone fixation element may incorporate a conical load bearing surface which contacts the linking member through a third channel in the coupling member. Upward axial movement provided by nut tightening forces the load bearing surface of the bone fixation element against the linking member, thereby securing both within the coupling member.Type: GrantFiled: August 9, 1996Date of Patent: February 29, 2000Assignee: Alphatech Manufacturing, Inc.Inventors: Shunshiro Yoshimi, Rick B. Delamarter, Angela Melton, Mike Stednitz
-
Patent number: 5562661Abstract: The present invention includes a bone fixation apparatus comprising a bone fixation element, a linking member, and a coupling member. The coupling member has a first channel for receiving a portion of the bone fixation element and a second channel for receiving a portion of the linking member. The first and second channels are configured within the coupling member so as to allow communication of a securing force from the bone fixation element to the linking member such that the bone fixation element is rigidly secured with respect to the linking member. The bone fixation element may incorporate a conical load bearing surface which contacts the linking member through a third channel in the coupling member. Upward axial movement provided by nut tightening forces the load bearing surface of the bone fixation element against the linking member, thereby securing both within the coupling member.Type: GrantFiled: March 16, 1995Date of Patent: October 8, 1996Assignee: Alphatec Manufacturing IncorporatedInventors: Shunshiro Yoshimi, Rick B. Delamarter, Angela Melton, Mike Stednitz